Home > Insider Trading > Filing (0001181431-12-043211)

Filing Details

Accession Number:: 0001181431-12-043211
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-08-02 16:04:16
Reporting Period:: 2012-07-31

Filing Date:: 2012-08-02
Accepted Time:: 2012-08-02 16:04:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1174940	Oragenics Inc	ORNI	Pharmaceutical Preparations (2834)	593410522

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1234877	Beverly Koski	1500 West University Parkway Sarasota FL 34243	No	No	Yes	No
1234878	L Christine Koski	1500 West University Parkway Sarasota FL 34243	Yes	No	Yes	No
1234879	Koski Family Lp	1500 West University Parkway Sarasota FL 34243	No	No	Yes	No
1234880	C Robert Koski	1500 West University Parkway Sarasota FL 34243	Yes	No	Yes	No
1234881	L Thomas Koski	1500 West University Parkway Sarasota FL 34243	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-31	1,692,123	$1.50	9,767,742	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	11,400	Direct
Common Stock	451,066	Direct
Common Stock	469,666	Direct
Common Stock	497,666	Indirect	By Trusts
Common Stock	10,000	Indirect	By Koski Management, Inc.

Footnotes

Pursuant to the terms of the Loan Agreement ("Loan Agreement") dated as of March 23, 2012 between Oragenics, Inc. (the "Company") and the Koski Family Limited Partnership ("KFLP"), the debt (including accrued but unpaid interest) represented thereby was subject to automatic conversion at the time of a qualified financing in an amount of no less than $5.0 million and on the same terms as such qualified financing. The Company consummated a financing on July 31, 2012 meeting the terms of a qualified financing, and the outstanding debt in the aggregate amount of $2,538,184.93 (consisting of a principal amount of $2,500,000 and accrued interest of $38,184.93) was converted into 1,692,123 shares of restricted common stock based upon the purchase price of $1.50 per share applicable to the qualified financing.
Shares owned directly by Koski Family Limited Partnership. Shares owned indirectly by Beverly Koski (through Koski Management, Inc. solely owned by Beverly Koski), Christine L. Koski, Robert C. Koski and Thomas L. Koski, each of whom is a general partner of the partnership or the controlling person of a corporate general partner of the partnership.
Each reporting person disclaims beneficial ownership of all indirectly owned securities in excess of such reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose.
Shares owned directly by Robert C. Koski.
Shares owned directly by Christine L. Koski.
Shares owned directly by Thomas L. Koski.
Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (100,000 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (100,000 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (100,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (100,000 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (97,666 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest.
Shares owned indirectly by Beverly Koski (through Koski Management, Inc).